Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04230928 · ClinicalTrials.gov registry record · NA
Giving a Low Carbohydrate Diet to Overcome Hypertension
A NA study, sponsored by Baylor Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT04230928: Completed NA study, sponsored by Baylor Research Institute.
NCT04230928 is a NA study that has completed, run by Baylor Research Institute. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04230928, a NA study, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
This study will test the preliminary efficacy of adding a very low carbohydrate dietary intervention to the evidence-based DPP-GLB on blood pressure reductions for lower-income AA men and women in a community-based clinic.
Primary Outcome
Measure changes in both systolic and diastolic blood pressure using digital sphygmomanometer; NOTE: Only Systolic BP is primary outcome, diastolic change will be a secondary outcome measure
Interventions
- OTHER Very low carbohydrate diet
- OTHER Standard DPP-GLB diet
- BEHAVIORAL Standard DPP-GLB program modules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2020-03-05 |
| Est. Completion | 2023-06-30 |
| Phase | NA |
What the finished NCT04230928 record still lists
NCT04230928 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which Very low carbohydrate diet is the first listed.
NCT04230928 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04230928 about?
NCT04230928 is a clinical study titled "Giving a Low Carbohydrate Diet to Overcome Hypertension". This study will test the preliminary efficacy of adding a very low carbohydrate dietary intervention to the evidence-based DPP-GLB on blood pressure reductions for lower-income AA men and women in a community-based clinic.
What is the current status of trial NCT04230928?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2020-03-05. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT04230928?
The interventions under investigation include: Very low carbohydrate diet (OTHER), Standard DPP-GLB diet (OTHER), Standard DPP-GLB program modules (BEHAVIORAL).
Who is sponsoring clinical trial NCT04230928?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04230928's enrollment target sits among peer trials
64 1147th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI